Sandoz sells US copies of 3 of the blockbuster drugs on this tracker, is approved for 5 more, and has 4 filed or in development. Those brands earned $80.0B in 2025. No other maker we follow is lined up to copy more of these drugs.
| Drug | Sandoz's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| Stelara PyzchivaBiosimilar · Johnson & Johnson · US LOE 2025 | FDA-approved 28 Jun 2024; launched Feb 2025; interchangeable With Samsung Bioepis |
7 on sale · 0 approvedof 7 other makers listed | $6.1B |
| Prolia JubbontiBiosimilar · Amgen · US LOE 2025 | FDA-approved 5 Mar 2024; launched 2 Jun 2025; interchangeable; first interchangeable biosimilar; its exclusivity as the only interchangeable ended 29 Oct 2025 | 6 on sale · 3 approvedof 10 other makers listed | $4.4B |
| Xgeva WyostBiosimilar · Amgen · US LOE 2025 | FDA-approved 5 Mar 2024; launched 2 Jun 2025; interchangeable; first interchangeable biosimilar; its exclusivity as the only interchangeable ended 29 Oct 2025 | 5 on sale · 4 approvedof 10 other makers listed | $2.1B |
| Drug | Sandoz's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| FarxigaGeneric · AstraZeneca · US LOE 2026 | FDA-approved 6 Apr 2026 | 2 on sale · 12 approvedof 14 other makers listed | $8.4B |
| PomalystGeneric · Bristol Myers Squibb · US LOE 2026 | FDA-approved 31 Aug 2026 | 4 on sale · 5 approvedof 10 other makers listed | $2.7B |
| JanuviaGeneric · Merck · US LOE 2026 | FDA-approved 14 Jan 2026 | 2 on sale · 0 approvedof 2 other makers listed | $2.5B |
| XtandiGeneric · Tablets · Astellas / Pfizer · US LOE 2027 | Tablets: FDA-approved 20 Apr 2026 | 0 on sale · 1 approvedof 5 other makers listed | ≈$6.0B |
| Enbrel ErelziBiosimilar · Amgen · US LOE 2029 | FDA-approved 30 Aug 2016; barred by court until 2029 | 0 on sale · 1 approvedof 1 other maker listed | $2.2B |
| Drug | Sandoz's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| LynparzaGeneric · AstraZeneca / Merck · US LOE 2027 | Filed with the FDA; settled Apr 2026, terms confidential | 0 on sale · 1 approvedof 3 other makers listed | $3.3B |
| OtezlaGeneric · Amgen · US LOE 2028 | Filed with the FDA; barred by court until Feb 2028 | 0 on sale · 5 approvedof 8 other makers listed | $2.3B |
| RinvoqGeneric · AbbVie · US LOE 2037 | Filed with the FDA; settled Sep 2025; US entry allowed from Apr 2037. Assuming pediatric exclusivity is granted | 0 on sale · 0 approvedof 4 other makers listed | $8.3B |
| Drug | Sandoz's status | Other makers listed | 2025 brand sales |
|---|---|---|---|
| KeytrudaBiosimilar · Merck · US LOE 2028 | In clinical trials | 0 on sale · 0 approvedof 9 other makers listed | $31.7B |
Copies not yet on sale, by the earliest year each could reach the US market: a settlement or court date where one is public, otherwise the brand's US exclusivity date. "Now" means that date has passed. Court rulings and new patents can move these.
The brand owner's US sales, as it reports them. They show how fast copies took the market, not Sandoz's own sales. See the launch tracker →
Each row is a copy Sandoz sells, holds an approval for, has filed, or is developing, for one of the 63 blockbuster drugs this site tracks. It is not Sandoz's full portfolio. "Other makers listed" counts the other companies on the same drug's list: how many sell a copy and how many more hold an approval. Brand owners and the FDA don't always name every filer, so a list can be incomplete; the drug page says so where we know.
2025 sales are what each brand earned, the size of the market at stake. They are not Sandoz's sales; several makers usually share a market once copies launch.
Every row is sourced on its drug's page: FDA Orange Book and Purple Book approvals, company releases and filings for launches, and court and company records for settlements. Company facts: MarketScreener.